Mary Price, MA
Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts
Original Research
Baseline Cardiovascular Risk Factors in Patients With Severe Mental Illness (SMI) and Second Generation Antipsychotic Use From the Fixed Dose Intervention Trial of New England Enhancing Survival in SMI (FITNESS)
January 8, 2025
Despite well-documented cardiovascular disease (CVD) morbidity and mortality, CVD risks among people with severe mental illness who use antipsychotics are common and frequently untreated.
